Investigation of the molecular mechanisms underlying metastasis in prostate cancer by gene expression profiling

Zhang,Xinghua; Yao,Xiaoli; Qin,Cong; Luo,Pengcheng; Zhang,Jie

doi:10.3892/etm.2016.3376

Investigation of the molecular mechanisms underlying metastasis in prostate cancer by gene expression profiling

Authors:
- Xinghua Zhang
- Xiaoli Yao
- Cong Qin
- Pengcheng Luo
- Jie Zhang
View Affiliations

Affiliations: Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: May 20, 2016 https://doi.org/10.3892/etm.2016.3376
Pages: 925-932
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to screen potential genes associated with metastatic prostate cancer (PCa), in order to improve the understanding of the mechanisms underlying PCa metastasis. The GSE3325 microarray dataset, which was downloaded from the Gene Expression Omnibus database, consists of seven clinically localized PCa samples, six hormone-refractory metastatic PCa samples and six benign prostate tissue samples. The Linear Models for Microarray Data package was used to identify differentially-expressed genes (DEGs) and a hierarchical cluster analysis for DEGs was performed with the pheatmap package. Furthermore, potential functions for the DEGs were predicted by a functional enrichment analysis. Subsequently, microRNAs (miRNAs) potentially involved in the regulation of PCa metastasis were identified by WebGestalt software, and the miRNA‑DEG regulatory network was visualized using Cytoscape. In addition, a pathway enrichment analysis for DEGs in the regulatory network was performed. A total of 306 and 2,073 genes were differentially expressed in the clinically localized PCa and the metastatic PCa groups, respectively, as compared with the benign prostate group, of which 174 were differentially expressed in both groups. A number of the DEGs, including CAMK2D and SH3BP4, were significantly enriched in the cell cycle, and others, such as MAF, were associated with the regulation of cell proliferation. Furthermore, some DEGs (CAMK2D and PCDH17) were observed to be regulated by miR‑30, whereas others (ADCY2, MAF, SH3BP4 and PCDH17) were modulated by miR‑182. Additionally, ADCY2 and CAMK2D were distinctly enriched in the calcium signaling pathway. The present study identified novel DEGs, including ADCY2, CAMK2D, MAF, SH3BP4 and PCDH17, that may be involved in the metastasis of PCa.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 46:765–781. 2010. View Article : Google Scholar : PubMed/NCBI
3	Watahiki A and Wang Y, Morris J, Dennis K, O'Dwyer HM, Gleave M, Gout PW and Wang Y: MicroRNAs associated with metastatic prostate cancer. PLoS One. 6:e249502011. View Article : Google Scholar : PubMed/NCBI
4	Sun YX, Schneider A, Jung Y, Wang J, Dai J, Wang J, Cook K, Osman NI, Koh-Paige AJ, Shim H, et al: Skeletal localization and neutralization of the SDF-1 (CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res. 20:318–329. 2005. View Article : Google Scholar : PubMed/NCBI
5	Cheng L, Nagabhushan M, Pretlow TP, Amini SB and Pretlow TG: Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol. 148:1375–1380. 1996.PubMed/NCBI
6	Tripathi V, Popescu NC and Zimonjic DB: DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion. Oncogene. 33:724–733. 2013. View Article : Google Scholar : PubMed/NCBI
7	Hu L, Shi Y, Hsu JH, Gera J, Van Ness B and Lichtenstein A: Downstream effectors of oncogenic ras in multiple myeloma cells. Blood. 101:3126–3135. 2003. View Article : Google Scholar : PubMed/NCBI
8	Hall A: Rho family GTPases. Biochem Soc Trans. 40:1378–1382. 2012. View Article : Google Scholar : PubMed/NCBI
9	Khafagy R, Stephens T, Hart C, Ramani V, Brown M and Clarke N: In vitro effects of the prenyl transferase inhibitor AZD3409 on prostate cancer epithelial cells. J Clin Oncol. 22:47442004.
10	Toren P and Zoubeidi A: Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (review). Int J Oncol. 45:1793–1801. 2014.PubMed/NCBI
11	Zhang J, Patel L and Pienta KJ: CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 21:41–48. 2010. View Article : Google Scholar : PubMed/NCBI
12	Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, Cheresh DA and Karin M: Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature. 446:690–694. 2007. View Article : Google Scholar : PubMed/NCBI
13	Cai H, Smith DA, Memarzadeh S, Lowell CA, Cooper JA and Witte ON: Differential transformation capacity of Src family kinases during the initiation of prostate cancer. Proc Natl Acad Sci USA. 108:6579–6584. 2011. View Article : Google Scholar : PubMed/NCBI
14	Salagierski M and Schalken JA: Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2: ERG gene fusion. J Urol. 187:795–801. 2012. View Article : Google Scholar : PubMed/NCBI
15	Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V, Chen Y, Deng G, Tanaka Y and Dahiya R: Regulatory role of miR-203 in prostate cancer progression and metastasis. Clin Cancer Res. 17:5287–5298. 2011. View Article : Google Scholar : PubMed/NCBI
16	Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G and Jung K: Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 126:1166–1176. 2010.PubMed/NCBI
17	Gandellini P, Folini M and Zaffaroni N: Towards the definition of prostate cancer-related microRNAs: Where are we now? Trends Mol Med. 15:381–390. 2009. View Article : Google Scholar : PubMed/NCBI
18	Szczyrba J, Löprich E, Wach S, Jung V, Unteregger G, Barth S, Grobholz R, Wieland W, Stöhr R, Hartmann A, et al: The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res. 8:529–538. 2010. View Article : Google Scholar : PubMed/NCBI
19	Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
20	Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, et al: Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 8:393–406. 2005. View Article : Google Scholar : PubMed/NCBI
21	Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP: Exploration, normalization and summaries of high density oligonucleotide array probe level data. Biostatistics. 4:249–264. 2003. View Article : Google Scholar : PubMed/NCBI
22	Gautier L, Cope L, Bolstad BM and Irizarry RA: affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
23	Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 3:2004.PubMed/NCBI
24	Verhoeven KJ, Simonsen KL and McIntyre LM: Implementing false discovery rate control: Increasing your power. Oikos. 108:643–647. 2005. View Article : Google Scholar
25	Olson CF: Parallel algorithms for hierarchical clustering. Parallel Computing. 21:1313–1325. 1995. View Article : Google Scholar
26	Kolde R: Pheatmap: Pretty Heatmaps. R package version 0.7. 7. Journal. 2012.
27	Huang DW, Sherman BT, Tan Q, Collins JR, Alvord G, Roayaei J, Stephens R, Baseler MW, Lane HC and Lempicki RA: The DAVID Gene functional classification tool: A novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 8:R1832007. View Article : Google Scholar : PubMed/NCBI
28	Huang DW, Sherman BT and Lempicki RA: Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
29	Visel A, Alvarez-Bolado G, Thaller C and Eichele G: Comprehensive analysis of the expression patterns of the adenylate cyclase gene family in the developing and adult mouse brain. J Comp Neurol. 496:684–679. 2006. View Article : Google Scholar : PubMed/NCBI
30	Hagemann D, Bohlender J, Hoch B, Krause EG and Karczewski P: Expression of Ca²⁺/calmodulin-dependent protein kinase II delta-subunit isoforms in rats with hypertensive cardiac hypertrophy. Mol Cell Biochem. 220:69–76. 2001. View Article : Google Scholar : PubMed/NCBI
31	Prevarskaya N, Skryma R and Shuba Y: Calcium in tumour metastasis: New roles for known actors. Nat Rev Cancer. 11:609–618. 2011. View Article : Google Scholar : PubMed/NCBI
32	Liao J, Schneider A, Datta NS and McCauley LK: Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res. 66:9065–9073. 2006. View Article : Google Scholar : PubMed/NCBI
33	Rajan P, Sudbery IM, Villasevil ME, Mui E, Fleming J, Davis M, Ahmad I, Edwards J, Sansom OJ, Sims D, et al: Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur Urol. 66:32–39. 2014. View Article : Google Scholar : PubMed/NCBI
34	Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, Matese JC, Perou CM, Hurt MM, Brown PO and Botstein D: Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell. 13:1977–2000. 2002. View Article : Google Scholar PubMed/NCBI
35	White R and Kung H: miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene. 33:2495–2503. 2014. View Article : Google Scholar : PubMed/NCBI
36	Kao C, Martiniez A, Shi X, Yang J, Evans C, Dobi A, Devere White R and Kung H: miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene. 33:2495–2503. 2014. View Article : Google Scholar : PubMed/NCBI
37	Rasheed SA, Teo CR, Beillard EJ, Voorhoeve PM and Casey PJ: MicroRNA-182 and microRNA-200a control G-protein subunit α-13 (GNA13) expression and cell invasion synergistically in prostate cancer cells. J Biol Chem. 288:7986–7995. 2013. View Article : Google Scholar : PubMed/NCBI
38	Liu R, Li J, Teng Z, Zhang Z and Xu Y: Overexpressed microRNA-182 promotes proliferation and invasion in prostate cancer PC-3 cells by down-regulating N-myc downstream regulated gene 1 (NDRG1). PLoS One. 8:e689822013. View Article : Google Scholar : PubMed/NCBI
39	Nagasawa H, Uto Y, Sasaki H, Okamura N, Murakami A, Kubo S, Kirk KL and Hori H: Gc protein (vitamin D-binding protein): Gc genotyping and GcMAF precursor activity. Anticancer Res. 25:3689–3695. 2005.PubMed/NCBI
40	Yamamoto N, Naraparaju VR and Asbell SO: Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients. Cancer Res. 56:2827–2831. 1996.PubMed/NCBI
41	Yamamoto N, Suyama H and Yamamoto N: Immunotherapy for prostate cancer with Gc protein-derived macrophage-activating factor, GcMAF. Transl Oncolo. 1:65–72. 2008. View Article : Google Scholar
42	Sharad S, Srivastava A, Ravulapalli S, Parker P, Chen Y, Li H, Petrovics G and Dobi A: Prostate cancer gene expression signature of patients with high body mass index. Prostate Cancer Prostatic Dis. 14:22–29. 2011. View Article : Google Scholar : PubMed/NCBI
43	Coppola V, De Maria R and Bonci D: MicroRNAs and prostate cancer. Endocr Relat Cancer. 17:F1–F17. 2010. View Article : Google Scholar : PubMed/NCBI
44	Zhang K and Waxman DJ: PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesis. Mol Cancer. 9:3192010. View Article : Google Scholar : PubMed/NCBI
45	Dunlevy JR, Koppelman ED and Kolberg JB: The expression of a SH3BP4-related protein in retinal cells. Invest Ophthalmol Vis Sci. 46:2996. 2005.
46	Dunlevy JR, Berryhill BL, Vergnes JP, SundarRaj N and Hassell JR: Cloning, chromosomal localization and characterization of cDNA from a novel gene, SH3BP4, expressed by human corneal fibroblasts. Genomics. 62:519–524. 1999. View Article : Google Scholar : PubMed/NCBI
47	Lin YL, Xie PG, Wang L and Ma JG: Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy. Med Sci Monit. 20:1376–1382. 2014. View Article : Google Scholar : PubMed/NCBI
48	Tang X, Tang X, Gal J, Kyprianou N, Zhu H and Tang G: Detection of microRNAs in prostate cancer cells by microRNA array. Methods Mol Biol. 732:69–88. 2011. View Article : Google Scholar : PubMed/NCBI
49	Ma S, Chan YP, Kwan PS, Lee TK, Yan M, Tang KH, Ling MT, Vielkind JR, Guan XY and Chan KW: MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2. Cancer Res. 71:583–592. 2011. View Article : Google Scholar : PubMed/NCBI
50	He HC, Han ZD, Dai QS, Ling XH, Fu X, Lin ZY, Deng YH, Qin GQ, Cai C, Chen JH, et al: Global analysis of the differentially expressed miRNAs of prostate cancer in Chinese patients. BMC Genomics. 14:7572013. View Article : Google Scholar : PubMed/NCBI